US 11,859,251 B1
Identifaction of cancer biomarkers by alignment of nucleic acid sequences
Ekkehard Schutz, Gottingen (DE); Julia Beck, Gottingen (DE); and Howard Urnovitz, San Jose, CA (US)
Assigned to CHRONIX BIOMEDICAL, San Jose, CA (US)
Filed by Chronix Biomedical, San Jose, CA (US)
Filed on Jul. 1, 2019, as Appl. No. 16/459,049.
Application 15/339,667 is a division of application No. 13/088,551, filed on Apr. 18, 2011, abandoned.
Application 16/459,049 is a continuation of application No. 15/339,667, filed on Oct. 31, 2016, granted, now 10,378,064.
Claims priority of provisional application 61/324,890, filed on Apr. 16, 2010.
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); G16B 5/00 (2019.01)
CPC C12Q 1/6886 (2013.01) [G16B 5/00 (2019.02); C12Q 2600/112 (2013.01)] 13 Claims
 
1. A method of analyzing nucleic acid sequences, the method comprising:
(a) sequencing amplified acellular DNA from a population of cancer patients subsequent to whole genome amplification of DNA extracted from serum or plasma from said population of cancer patients, wherein said sequencing is performed with one or more individual sequence tags for sample identification, and wherein said sequencing generates at least 50,000 sequences per sample;
(b) electrically receiving sequence information obtained in (a) on a processor describing one or more of the sequenced amplified acellular DNA from the population of cancer patients;
(c) electrically receiving sequence information on said processor describing one or more DNA sequences from a cancer free control population;
(d) electrically performing an analysis comparing the information electrically received on the processor in steps (b) and (c) within a finite number of cluster regions of the human genome by aligning sequences within the finite number of cluster regions from said sequenced acellular DNA from the population of cancer patients with one or more sequences from acellular DNA obtained from the cancer free control population; and
(e) electrically identifying one or more biomarkers representative of the type of cancer presented by the population of cancer patients by the processor.